摘要
检查点分子抑制治疗对复发的原发性皮肤弥漫性大B细胞淋巴瘤-腿型（primary cutaneous diffuse large B-cell lymphoma, leg-type, PCDLBCL-LT)有效，我们在本研究中检测了29例PCDLBCL-LT病例的程序性死亡配体（programmed death ligands, PD-L) 1和PD-L2的表达情况。我们对肿瘤细胞进行了PD-L1/PD-L2与PAX5免疫组化双染；对浸润的巨噬细胞进行了 PD-L1/PD-L2与CD168或CD163免疫组化双染。我们还通过对CD3 (肿瘤浸润淋巴细胞）、FOXP3 (调节性T细胞）、细胞程序性死亡蛋白-1 (PD-L1) CD33 (髓源抑制性细胞）的免疫染色对PCDLBCL-LT的微环境进行表征。采用荧光原位杂交检测PD-L1/PD-L2的编码基因9p24.1。所有纳入病例中均有PD-L1的表达，可见大量PD-L1阳性的M2型巨噬细胞（CD68+CD163+）浸润，但仅有1例为肿瘤细胞阳性（PAX5+PD-L1+）。进行荧光原位杂交检测的26例病例中，21例结果正常。3例 (11.5%)为低度多体状态，其中就包括肿瘤细胞PD-L1阳性病例。有趣的是，2例（7.7%)表现为PD-L1/PD-L2位点分离模式，肿瘤细胞为PD-L2阳性。无9p24.1重排的24例病例中均未见PD-L2阳性肿瘤细胞。免疫检查点抑制剂治疗PCDLBCL-LT的复发患者可能间接通过免疫细胞来发挥作用，但对罕见的因9p24.1重排而肿瘤细胞表达PD-L2的病例无效。在以M2型巨噬细胞为主要免疫细胞的某些淋巴瘤亚型中，结合肿瘤相关巨噬细胞重编程的抗肿瘤策略值得密切关注。
庄翔 翻译 石毓君 审校
美国外科病理学杂志中文版第三期摘要No.5
Am J Surg Pathol ;42:326-334
The American Journal of Surgical Pathology中文版声明：
© Wolters Kluwer Health
The material is published by Wolters Kluwer Health with the permission of American Journal of Surgical Pathology.No part of this publication may be reproduced in any form,stored in a retrieval system or transmitted in any form,by any means,without prior written permission from Wolters Kluwer Health.Opinions expressed by the authors and advertisers are not necessarily those of the American Journal of Surgical Pathology, its affiliates,or of the Publisher.The American Journal of Surgical Pathology,its affiliates,and the Publisher disclaim any liability to any party for the accuracy,completeness,efficacy,or availability of the material contained in this publication (including drug dosages) or for any damages arising out of the use or non-use of any of the material contained in this publication.
Although advertising material is expected to conform to ethical (medical) standards,inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
美国外科病理学杂志
中文版
